Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lysergic acid diethylamide - MindMed/The University Hospital of Basel

Next Previous
X
Search
Drug Profile

Lysergic acid diethylamide - MindMed/The University Hospital of Basel

Alternative Names: D-lysergic acid diethylamide d-Tartrate - Mind Medicine; LSD - MindMed/The University Hospital of Basel; LSD D-tartrate; lysergide D-tartrate; MM-120

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The University Hospital of Basel
  • Developer Maastricht University; Mindmed; The University Hospital of Basel
  • Class Analgesics; Antidementias; Antidepressants; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Ergolines; Ergot alkaloids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anxiety disorders; Attention-deficit hyperactivity disorder; Cluster headache; Major depressive disorder
  • Preclinical Pain

Most Recent Events

  • 08 May 2024 MindMed plans to hold an end of phase II meeting with US FDA for Anxiety disorders in the second quarter of 2024
  • 04 May 2024 Efficacy data from a phase II clinical trials in Anxiety disorders released by Mindmed
  • 07 Mar 2024 Lysergic acid diethylamide - MindMed/The University Hospital of Basel receives Breakthrough Therapy status for Anxiety disorders in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top